← Back to Search

Topoisomerase I inhibitors

Etoposide for Small Cell Lung Cancer (Drugs-SNPs Trial)

Phase 2 & 3

Waitlist Available

Research Sponsored by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Clinical diagnosis of Small Cell Lung Cancer (SCLC)

Suitable for enough lung tissue biopsy of SCLC

Timeline

Screening 3 weeks

Treatment Varies

Follow Up duration at least 90 days

Awards & highlights

Drugs-SNPs Trial Summary

This trial will explore the relationship between a patient's genetic makeup and how well they respond to the drug etoposide, as well as any side-effects they may experience.

Who is the study for?

This trial is for adults over 22 with small cell lung cancer who can undergo a biopsy and have their blood drawn. They must be able to sign consent, have measurable disease, good organ function and performance status. It's not for those with serious allergies to drugs, multiple cancers, severe bleeding risks or infections, pregnant or breastfeeding individuals.Check my eligibility

What is being tested?

The study investigates how genetic differences (SNPs) in the topoisomerase II gene and CYP4503A4 gene affect the treatment outcomes and side effects of Etoposide in small cell lung cancer patients. The trial uses precise gene sequencing techniques.See study design

What are the potential side effects?

Etoposide may cause low white blood cell counts (increasing infection risk), hair loss, nausea, vomiting, diarrhea or constipation. There might also be allergic reactions like rashes or more serious ones that could require immediate medical attention.

Drugs-SNPs Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with Small Cell Lung Cancer.

Select...

My doctor can take a biopsy of my lung tissue.

Select...

My lung cancer was confirmed through a tissue biopsy.

Select...

I am 22 years old or older.

Drugs-SNPs Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ duration at least 90 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~duration at least 90 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and duration at least 90 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Find Etoposide Drug Targets' SNP Genotypes which are effectiveness-associated, and which are risk-associated.

Drugs-SNPs Trial Design

2Treatment groups

Experimental Treatment

Group I: ETOPOSIDE - UsualExperimental Treatment1 Intervention

Etoposide Injection Chemotherapy Etoposide Injection Usual Approach Group

Group II: ETOPOSIDE - StudyExperimental Treatment1 Intervention

Etoposide Capsule Chemotherapy Etoposide Capsule Study Approach Group

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

UnitedHealthcareOTHER

2 Previous Clinical Trials

592,548 Total Patients Enrolled

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairLead Sponsor

5 Previous Clinical Trials

1,840 Total Patients Enrolled

Han Xu, M.D., Ph.D., Sponsor-Investigator, IRB ChairLead Sponsor

3 Previous Clinical Trials

640 Total Patients Enrolled

Media Library

Etoposide (Topoisomerase I inhibitors) Clinical Trial Eligibility Overview. Trial Name: NCT01064466 — Phase 2 & 3

Small Cell Lung Cancer Research Study Groups: ETOPOSIDE - Study, ETOPOSIDE - Usual

Small Cell Lung Cancer Clinical Trial 2023: Etoposide Highlights & Side Effects. Trial Name: NCT01064466 — Phase 2 & 3

Etoposide (Topoisomerase I inhibitors) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01064466 — Phase 2 & 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Would it be possible for me to participate in this clinical trial?

"This clinical trial is looking for 600 participants with small cell lung carcinoma, aged 22 to 75. In order to be eligible, patients must have had the condition for at least 180 days and must be able to have a lung tissue biopsy. Additionally, the following criteria must be met: 1. Clinical diagnosis of Small cell lung cancer (SCLC), 2. Clinical lung tissue biopsy diagnosis of SCLC, 3. Suitable for enough lung tissue biopsy of SCLC, 4. Random and double blind, 5. Measurable disease, 6. Adequate organ functions."

Answered by AI

What conditions does ETOPOSIDE - Study help treat?

"ETOPOSIDE - This medication is most frequently utilized to manage small cell lung cancer (sclc). Additionally, it can be useful in treating metastatic thymic cancer, leukemia, myelocytic, acute, and advance directives."

Answered by AI

Can people below the age of 20 participate in this clinical research?

"The age limit for this study are individuals who are at least 22 but no older than 75."

Answered by AI

What does the research say about using etoposide to treat patients?

"There are presently 322 clinical trials underway researching the efficacy of ETOPOSIDE - Study. 95 of those are in the final Phase 3. Many of these studies are based in Houston, Texas, but there are a total of 15464 locations running these trials."

Answered by AI

Do we have the regulatory go-ahead to use ETOPOSIDE in this research?

"ETOPOSIDE - Study has been scored a 3 for safety by our team at Power. This is due to this being a Phase 3 trial, which signifies that there is data affirming its efficacy as well as multiple rounds of data affirming its safety."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Pharmacogenomics IND EXEMPT SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair 2017. "Pharmacogenomics IND EXEMPT SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01064466.

All > Metastatic Lung Cancer > Small Cell Lung Cancer